SCHEMBL23200418

SCHEMBL23200418

N#Cc1c(NC(=O)c2ccccc2N)sc2c1CCCC2

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 7/20 0.76
MAPK9 P45984 1/20 0.72
ALDH1A1 P00352 5/20 0.69
NPC1 O15118 4/20 0.69
HPGD P15428 4/20 0.69
RAB9A P51151 4/20 0.69
SMN1; SMN2 Q16637 4/20 0.69
KDM4E B2RXH2 3/20 0.69
THRB P10828 1/20 0.69
MEN1 O00255 6/20 0.68
KMT2A Q03164 6/20 0.68
LMNA P02545 2/20 0.62
SORT1 Q99523 1/20 0.61
GLA P06280 1/20 0.60
POLB P06746 1/20 0.58
MAPT P10636 1/20 0.58
ALOX15 P16050 1/20 0.58
RECQL P46063 1/20 0.58
HSD17B10 Q99714 1/20 0.58
TDP1 Q9NUW8 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23200287 0.98 MAPK10 (0.72) MAPK10MAPK9ALDH1A1NPC1HPGD
SCHEMBL3279549 0.87 MEN1 (0.80) MAPK10MAPK9ALDH1A1NPC1HPGD
SCHEMBL15281390 0.87 MAPK10 (0.77) MAPK10MAPK9ALDH1A1NPC1HPGD
Gw572738X SCHEMBL3284953 0.86 MAPK10 (1.00) MAPK10MAPK9ALDH1A1NPC1HPGD
SCHEMBL3277942 0.86 MAPK10 (0.76) MAPK10MAPK9ALDH1A1NPC1HPGD
SCHEMBL3278507 0.86 MAPK10 (1.00) MAPK10MAPK9ALDH1A1NPC1HPGD
Gw620972X SCHEMBL157875 0.84 MAPK10 (1.00) MAPK10MAPK9ALDH1A1NPC1HPGD
SCHEMBL31074969 0.83 MAPK10 (0.98) MAPK10MAPK9ALDH1A1NPC1HPGD
SCHEMBL3284934 0.83 KMT2A (0.96) MAPK10MAPK9ALDH1A1NPC1HPGD
SCHEMBL3285611 0.83 MAPK10 (1.00) MAPK10MAPK9ALDH1A1NPC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12065421-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes PROMEGA CORPORATION (US) 2024-08-20 US disclosed
EP-4140991-B1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES PROMEGA CORP (US) 2024-05-15 EP disclosed
EP-4140991-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES Promega Corporation (US) 2023-03-01 EP disclosed
US-20220365086-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES PROMEGA CORPORATION 2022-11-17 US disclosed
EP-3802514-B1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES PROMEGA CORP (US) 2022-08-03 EP disclosed
US-11390599-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes PROMEGA CORPORATION (US) 2022-07-19 US disclosed
EP-3802514-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES Promega Corporation (US) 2021-04-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220365086-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES LUC7L2, LYPLAL1, GUSB MAPK10 1869/4885MAPK9 2875/4885ALDH1A1 1554/4885
US-12065421-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes LUC7L2, LYPLAL1, GUSB MAPK10 1869/4885MAPK9 2875/4885ALDH1A1 1554/4885
US-11390599-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes LUC7L2, LYPLAL1, GUSB MAPK10 1869/4885MAPK9 2875/4885ALDH1A1 1554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.